LSKL, Inhibitor of Thrombospondin TSP-1是 TGF-β 的激活剂。
产品描述
LSKL, Inhibitor of Thrombospondin TSP-1 acetate is activation of TGF-β .
体内活性
Administration of LSKL peptide attenuated Smad2 phosphorylation at 6 h. S-phase entry of hepatocytes was accelerated at 24 and 48 h by LSKL peptide, which resulted in faster recovery of the residual liver and bodyweight.?Haematoxylin and eosin tissue staining and blood biochemical examinations revealed no significant adverse effects following the two LSKL peptide administrations.?In the clinical setting, plasma TSP-1 levels were lowest on the first day after hepatectomy.?However, plasma TSP-1 levels at this stage were significantly higher in patients with subsequent liver dysfunction compared with levels in those without liver dysfunction following hepatectomy
动物实验
Mice were operated on with a 70 per cent hepatectomy or sham procedure. Operated mice received either LSKL peptide or normal saline intraperitoneally at abdominal closure and 6 h after hepatectomy. Perioperative plasma TSP-1 levels were measured by enzyme-linked immunosorbent assay in patients undergoing hepatectomy.
Cas No.
T7676
分子式
C25H44F6N6O9
分子量
686.64
别名
LSKL, Inhibitor of Thrombospondin TSP-1
储存和溶解度
DMSO:10 mM
Powder: -20°C for 3 years
In solvent: -80°C for 2 years